
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)*

Cue Biopharma, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

22978P106

(CUSIP Number)

09/30/2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)
-

SCHEDULE 13G

CUSIP No. 22978P106

Names of Reporting Persons

1

Bleichroeder LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

	Sole Voting Power
5	6,127,662.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	6,127,662.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	6,127,662.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>
11	Percent of class represented by amount in row (9)
	9.99 %
12	Type of Reporting Person (See Instructions)
	IA

Comment for Type of Reporting Person: Relating to item 11 on this page: Based on 60,207,717 shares reported by the Issuer to be outstanding plus 1,130,422 shares of Common Stock underlying warrants held by the Reporting Persons

SCHEDULE 13G

CUSIP No. 22978P106

1	Names of Reporting Persons
	Bleichroeder Holdings LLC
	Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/> (a)
	<input type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization
	DELAWARE
	Sole Voting Power
5	6,127,662.00
Number of Shares Beneficially Owned by Each Reporting Person With:	Shared Voting Power
6	0.00
	Sole Dispositive Power
7	6,127,662.00
	Shared Dispositive Power
8	0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person
	6,127,662.00

10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Percent of class represented by amount in row (9)

11

9.99 %

Type of Reporting Person (See Instructions)

12

HC

Comment for Type of Reporting Person: Relating to item 11 on this page: Based on 60,207,717 shares reported by the Issuer to be outstanding plus 1,130,422 shares of Common Stock underlying warrants held by the Reporting Persons

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Cue Biopharma, Inc.

Address of issuer's principal executive offices:

(b)

40 Guest Street, Boston, MA 02135

Item 2.

Name of person filing:

(a)

Bleichroeder Holdings LLC Bleichroeder LP

Address or principal business office or, if none, residence:

(b)

1345 Avenue of the Americas, 47th Floor New York, NY 10105

Citizenship:

(c)

Delaware, USA

Title of class of securities:

(d)

Common Stock, par value \$0.001 per share

CUSIP No.:

(e)

22978P106

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a)

See cover page.

(b)

Percent of class:

See cover page. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See cover page.

(ii) Shared power to vote or to direct the vote:

See cover page.

(iii) Sole power to dispose or to direct the disposition of:

See cover page.

(iv) Shared power to dispose or to direct the disposition of:

See cover page.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Bleichroeder LP ("Bleichroeder"), an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 6,127,662 shares, or 9.99%, of the common stock ("Common Stock") reported by the Issuer as outstanding. Bleichroeder is the beneficial owner of Common Stock, warrants with a 4.99% limit on the exercise of such warrants, warrants with a 9.99% limit on the exercise such such warrants, and pre-funded warrants with a 9.99% limit on the exercise such such warrants. If there was no 4.99% limit on the exercise of certain warrants, nor a 9.99% limit on the exercise of certain warrants and and pre-funded warrants, Bleichroeder would be deemed to be the beneficial owner of 4,997,240 shares of Common Stock, 306,278 shares of Common Stock issuable upon exercise of the warrants subject to a 4.99% limit, 1,250,000 shares of Common Stock issuable upon exercise of the warrants subject to a 9.99% limit, and 2,964,366 shares of Common Stock issuable upon exercise of the pre-funded warrants subject to a 9.99% limit, representing 14.7% of the outstanding shares of Common Stock. Clients of Bleichroeder have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

See exhibit 99.1

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bleichroeder LP

Signature: Michael M. Kellen
Name/Title: Chairman And CO-CEO
Date: 10/07/2024

Bleichroeder Holdings LLC

Signature: Michael M. Kellen
Name/Title: Chairman And CO-CEO
Date: 10/07/2024

Exhibit Information

Exhibit 99.1: Subsidiary Information

The identity and the Item 3 classification of the relevant subsidiary is: Bleichroeder LP, which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).